Drew G M, Hilditch A, Levy G P
Br J Pharmacol. 1978 Jul;63(3):471-4. doi: 10.1111/j.1476-5381.1978.tb07799.x.
1 The effects of the combined alpha- and beta-adrenoceptor blocking drug, labetalol, on the uptake of [3H]-(-)-noradrenaline into the isolated vas deferens of the rat have been determined and compared with those of some other alpha-adrenoceptor blocking drugs and cocaine. 2 Labetalol, like cocaine, produced a simple competitive inhibition of [3H]-(-)-noradrenaline uptake and was about 4 times less potent than cocaine. It is concluded that labetalol is a potent inhibitor of uptake1. Phentolamine and thymoxamine also inhibited [3H]-(-)-noradrenaline uptake, and were respectively 8 and 14 times less potent than cocaine. Tolazoline, piperoxan and yohimbine were inactive in concentrations up to 30 microgram/ml. 3 The uptake1 blocking action of labetalol could explain, at least in part, the previously reported difference in its ability to block noradrenaline and phenylephrine vasopressor responses in the anaesthetized dog. 4 The possibility that uptake1 inhibitory concentrations of labetalol could be present in the blood of subjects receiving normal antihypertensive doses of the drug is discussed.
已测定联合使用的α和β肾上腺素能受体阻断药拉贝洛尔对[3H]-(-)-去甲肾上腺素摄取进入大鼠离体输精管的影响,并与其他一些α肾上腺素能受体阻断药及可卡因的影响进行了比较。
拉贝洛尔与可卡因一样,对[3H]-(-)-去甲肾上腺素的摄取产生单纯竞争性抑制,其效力约为可卡因的1/4。得出结论,拉贝洛尔是摄取1的强效抑制剂。酚妥拉明和噻吗洛尔也抑制[3H]-(-)-去甲肾上腺素的摄取,其效力分别为可卡因的1/8和1/14。妥拉唑啉、哌罗克生和育亨宾在浓度高达30微克/毫升时无活性。
拉贝洛尔的摄取1阻断作用至少可以部分解释先前报道的其在麻醉犬中阻断去甲肾上腺素和去氧肾上腺素升压反应能力方面的差异。
讨论了接受正常降压剂量该药的受试者血液中可能存在摄取1抑制浓度拉贝洛尔的可能性。